Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Chaput N, Schartz NE, André F, Taïeb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L. Chaput N, et al. Among authors: ferrantini m. J Immunol. 2004 Feb 15;172(4):2137-46. doi: 10.4049/jimmunol.172.4.2137. J Immunol. 2004. PMID: 14764679
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.
Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L. Conforti R, et al. Among authors: ferrantini m. Cancer Res. 2010 Jan 15;70(2):490-500. doi: 10.1158/0008-5472.CAN-09-1890. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068181
Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M. Santodonato L, et al. Among authors: ferrantini m. J Immunol. 2003 May 15;170(10):5195-202. doi: 10.4049/jimmunol.170.10.5195. J Immunol. 2003. PMID: 12734367
Cytokines as natural adjuvants for vaccines: where are we now?
Rizza P, Ferrantini M, Capone I, Belardelli F. Rizza P, et al. Among authors: ferrantini m. Trends Immunol. 2002 Aug;23(8):381-3. doi: 10.1016/s1471-4906(02)02276-7. Trends Immunol. 2002. PMID: 12133794 No abstract available.
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L. Di Pucchio T, et al. Among authors: ferrantini m. Cancer Res. 2006 May 1;66(9):4943-51. doi: 10.1158/0008-5472.CAN-05-3396. Cancer Res. 2006. PMID: 16651452 Clinical Trial.
Dendritic cells and cytokines in immune rejection of cancer.
Ferrantini M, Capone I, Belardelli F. Ferrantini M, et al. Cytokine Growth Factor Rev. 2008 Feb;19(1):93-107. doi: 10.1016/j.cytogfr.2007.10.003. Epub 2007 Dec 3. Cytokine Growth Factor Rev. 2008. PMID: 18054517 Review.
50 results